Psoriasis pathogenesis and treatments targeting these pathways

Steven R. Feldman, MD, PhD

The understanding of the pathogenesis of psoriasis has been increasing in recent years. Treatments are more targeted to specific aspects of the immune system.

“Now we have treatments that specifically target that pathway [TH17 pathway], and I think they’re not only highly effective but probably a lot safer than what we were using before,” advises Dr. Steven Feldman. “These new treatments, I think, are getting to the root of the problem.”

In this video interview, Dr. Feldman discusses the pathogenesis of psoriasis, why it is necessary for patients to continue to treat their condition even after seeing clearance, and how patient compliance impacts disease development.


Dr. Feldman is with the Department of Dermatology as well as the Department of Pathology and Social Sciences & Health Policy, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, North Carolina. Dr. Feldman has received consulting, research, or speaking support from Galderma Laboratories, LEO Pharma, Ortho Dermatologics, and Sun Pharmaceutical Industries.

Related articles from

Dermatology therapies evolve as disease knowledge and investment grow
Nerves, Neuropeptides, and the Nervous System in the Pathogenesis of Psoriasis
Psoriasis Risk Factors and Triggers